Allergic Fungal Rhinosinusitis (AFRS)

Overview

Epidemiology

• Most common in young immunocompetent adults (mean age 21-33 years)
• Predilection for warm, humid geographic regions (e.g., the Mississippi basin in the USA, tropical regions)
• Strongly associated with lower socioeconomic status and atopic background
• Comorbid asthma is common; aspirin-sensitive asthma suggests eosinophilic mucin rhinosinusitis (EMRS) rather than classic AFRS
• Scott-Brown's Otorhinolaryngology, Vol 1, p. 260

Pathophysiology

1. Inhaled fungal spores (particularly dematiaceous fungi) are encountered by an atopic sinonasal mucosa
2. Fungal antigens drive IgE-mediated mast cell and eosinophil activation
3. This creates an inflammatory cascade involving IL-25, IL-33, and TSLP (Th2 epithelial cytokines), eosinophil recruitment, and mucus stasis
4. Ostial obstruction leads to accumulation of eosinophilic (allergic) mucin containing fungal debris
5. The expanding mucin mass causes sinus expansion, bony demineralization, remodeling, and erosion - without mucosal invasion
6. Secondary Staphylococcus aureus biofilm may co-exist, with superantigens amplifying the eosinophilic response

• Dematiaceous (pigmented) species: Bipolaris, Curvularia, Alternaria, Exophiala, Fusarium
• Aspergillus species (less common, more typical in hot dry climates)
• K.J. Lee's Essential Otolaryngology, p. 559-560

Allergic Mucin (Eosinophilic Mucin)

• Gross appearance: Thick, viscous, greenish-brown, "peanut butter" consistency
• Histology:
  • Lamellated sheets of eosinophils
  • Charcot-Leyden crystals (bipyramidal crystals from eosinophil breakdown)
  • Branching, non-invasive fungal hyphae (may be sparse or absent)
  • Necrotic inflammatory cell debris

Clinical Presentation

Diagnostic Criteria: Bent and Kuhn (1994)

Imaging

CT Scan (modality of choice - non-contrast)

• Ethmoid sinuses most commonly involved
• Heterogeneous, increased attenuation of sinus contents (due to calcium salts, heavy metals, protein concentration in mucin)
• Sinus expansion with bony demineralization, remodeling, or frank erosion
• Can be unilateral or bilateral (unilateral is more classic; bilateral suggests EMRS)
• Erosion of lamina papyracea, skull base possible in advanced disease

MRI

• T1: isointense to hypointense (high protein, dehydrated mucin)
• T2: hypointense to signal void (classic finding - helps distinguish from bacterial sinusitis)
• Peripheral mucosal enhancement with contrast; allergic mucin does NOT enhance
• K.J. Lee's Essential Otolaryngology, p. 561

Spectrum of Disease / Related Entities

Treatment

1. Surgery - Endoscopic Sinus Surgery (ESS)

• Goals: Complete removal of allergic mucin and fungal debris, polypectomy, meticulous ethmoidectomy, wide ostioplasty
• Thorough debridement is essential - residual mucin perpetuates the inflammatory response and drives revision surgery
• Caution: Significant bony erosion means dura and periorbita may be adherent to mucosa and easily violated
• Micro-debriders should be used with extreme care near areas of orbital or skull base dehiscence
• Balloon sinusotomy is controversial in severe AFRS/polyposis disease; use is more appropriate for mild-moderate disease

2. Corticosteroids

• Prednisone ~0.5 mg/kg/day for 2-3 weeks, perioperative, then tapered over several days to weeks
• Reduces post-operative mucosal disease and inflammatory markers
• Risk: significant side effects with high-dose prolonged use; disease may recur on cessation

• Intranasal steroid sprays or budesonide irrigations - used concomitantly and long-term
• Tapered after stabilization of mucosal health

3. Immunotherapy (IT)

• Decreases polyp recurrence, nasal crusting, systemic corticosteroid use
• Reduces revision surgery rates (11.1% with IT vs. 33% without IT in one study - Bassichis et al.)
• Concern about theoretical Type III (immune complex) reaction from fungal-specific IgG has not been substantiated - no such reactions reported to date
• IT may begin post-operatively once surgical sites have healed

4. Antifungals

• Sparse evidence; Cochrane reviews of both topical and oral antifungals show no benefit in CRS
• Oral or topical antifungals are NOT recommended as routine therapy in AFRS
• K.J. Lee's Essential Otolaryngology, p. 562

5. Biologics (Emerging - 2025 Evidence)

6. Antibiotics

• Culture-directed antibiotics for frank mucopurulence
• AFRS exacerbations are often heralded by secondary acute bacterial sinus infections
• Some clinicians use empirical anti-staphylococcal agents or mupirocin irrigation post-operatively (given the S. aureus biofilm association)

7. Leukotriene Modulators

• No established evidence to support montelukast in AFRS (only one case report of benefit)

Post-operative Surveillance

• Early detection of disease recurrence
• Surveillance for new bone erosion
• Guided topical medication delivery into widely patent sinuses
• Timely initiation of revision surgery if needed
• Cummings Otolaryngology, Head and Neck Surgery, p. 892

Key Differentials

Recent Evidence Update

• A 2025 meta-analysis (PMID 40552669) confirms short-term biologic efficacy (particularly omalizumab and dupilumab) in recalcitrant AFRS.
• A 2026 systematic review (PMID 42061107) characterizes AFRS fungal species distribution in the Eastern Mediterranean, where Aspergillus and dematiaceous fungi both feature prominently.
• A 2025 meta-analysis on post-operative oral corticosteroids (PMID 40270102) reinforces the benefit of perioperative steroid use in CRS/AFRS following ESS.

• K.J. Lee's Essential Otolaryngology, 12th Ed., pp. 559-562
• Cummings Otolaryngology Head and Neck Surgery, 7th Ed., pp. 876, 892
• Scott-Brown's Otorhinolaryngology, Vol 1, pp. 259-261
• Harrison's Principles of Internal Medicine, 22E (2025), p. 300